Get started
Author

Juan José Gorgojo Martínez

Observed names: Gorgojo-Martinez, Juan J., Gorgojo-Martínez Jj, J. J. Gorgojo-Martinez, J.J. Gorgojo-Martínez, JUAN J. GORGOJO-MARTINEZ, JUAN JOSE GORGOJO-MARTINEZ, Juan J. Gorgojo Martínez, Juan J. Gorgojo-Martinez, Juan J. Gorgojo-Martínez, Juan J. Gorgojo‐Martinez, Juan J. Gorgojo‐Martínez, Juan Jose Gorgojo Martínez, Juan José Gorgojo-Martinez, Juan José Gorgojo-Martínez
ORCID: 0000-0002-8679-0968
Observed ORCID: 0000-0002-8679-0968
OpenAlex ID: A5076277987
Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus
2022 · Juan J. Gorgojo-Martínez, Pedro Mezquita-Raya, et al. · Journal of Clinical Medicine · 345
PDF
GLP-1 Receptor Agonists and Diabetic Kidney Disease: A Call of Attention to Nephrologists
2020 · José Luis Górriz, María José Soler, et al. · Journal of Clinical Medicine · 144
PDF
Effectiveness and tolerability of orlistat and liraglutide in patients with obesity in a real‐world setting: The XENSOR Study
2019 · Juan J. Gorgojo‐Martínez, Belen Basagoiti‐Carreño, et al. · International Journal of Clinical Practice · 82
PDF
Effectiveness and tolerability of liraglutide in patients with type 2 diabetes mellitus and obesity after bariatric surgery
2016 · Juan J. Gorgojo-Martínez, Gara Feo-Ortega, et al. · Surgery for Obesity and Related Diseases · 60
Clinical Recommendations for Managing Genitourinary Adverse Effects in Patients Treated with SGLT-2 Inhibitors: A Multidisciplinary Expert Consensus
2024 · Juan J. Gorgojo-Martínez, José L. Górriz, et al. · Journal of Clinical Medicine · 47
PDF
Switching between GLP‐1 receptor agonists in clinical practice: Expert consensus and practical guidance
2020 · Akshay B. Jain, Amar Ali, et al. · International Journal of Clinical Practice · 44
PDF
Real-world effectiveness and safety of dapagliflozin therapy added to a GLP1 receptor agonist in patients with type 2 diabetes
2016 · J.J. Gorgojo-Martínez, C. Serrano-Moreno, et al. · Nutrition Metabolism and Cardiovascular Diseases · 29
Real-world clinical outcomes and predictors of glycaemic and weight response to exenatide once weekly in patients with type 2 diabetes: The CIBELES project
2018 · Juan José Gorgojo-Martínez, Manuel Angel Gargallo-Fernández, et al. · International Journal of Clinical Practice · 25
Documento de posicionamiento: evaluación y manejo de la hipoglucemia en el paciente concon diabetes mellitus. Grupo de Trabajo de Diabetes Mellitus de la Sociedad Española de Endocrinología y Nutrición
2013 · Pedro Mezquita-Raya, Rebeca Reyes-García, et al. · Endocrinología y Nutrición · 23
Assessing the cost-effectiveness of a once-weekly GLP-1 analogue versus an SGLT-2 inhibitor in the Spanish setting: Once-weekly semaglutide versus empagliflozin
2019 · Juan José Gorgojo-Martínez, Samuel J. P. Malkin, et al. · Journal of Medical Economics · 20
PDF
Comprehensive Cardiovascular and Renal Protection in Patients with Type 2 Diabetes
2023 · Almudena Castro Conde, Domingo Marzal Martín, et al. · Journal of Clinical Medicine · 19
PDF
Position statement: Hypoglycemia management in patients with diabetes mellitus. Diabetes Mellitus Working Group of the Spanish Society of Endocrinology and Nutrition
2013 · Pedro Mezquita-Raya, Rebeca Reyes-García, et al. · Endocrinología y Nutrición (English Edition) · 18
Oral Semaglutide and Heart Failure Outcomes in Persons With Type 2 Diabetes
2026 · Rodica Pop-Busui, Søren Rasmussen, et al. · JAMA Internal Medicine · 14
PDF
Nuevos fármacos para la reducción del riesgo cardiovascular en pacientes con diabetes mellitus tipo 2
2019 · J.J. Gorgojo-Martínez · Hipertensión y Riesgo Vascular · 14
Impact of Oral Semaglutide on Kidney Outcomes in People With Type 2 Diabetes: Results From the SOUL Randomized Trial
2025 · Johannes F.E. Mann, Nikolaus Marx, et al. · Diabetes Care · 13
PDF
Adipocentric Strategy for the Treatment of Type 2 Diabetes Mellitus
2025 · Juan J. Gorgojo-Martínez · Journal of Clinical Medicine · 12
PDF
Beyond the Glycaemic Control of Dapagliflozin: Impact on Arterial Stiffness and Macroangiopathy
2022 · José M. González-Clemente, María García-Castillo, et al. · Diabetes Therapy · 11
PDF
Real-World Clinical Outcomes Associated with Canagliflozin in Patients with Type 2 Diabetes Mellitus in Spain: The Real-Wecan Study
2020 · Juan J. Gorgojo-Martínez, Manuel A. Gargallo-Fernández, et al. · Journal of Clinical Medicine · 10
PDF
Déficit de yodo en una población de mujeres embarazadas pertenecientes a un área con leve deficiencia de yodo
2006 · Francisca Almodóvar Ruiz, Juan José Gorgojo Martínez, et al. · Endocrinología y Nutrición · 10
Effectiveness and Tolerability of the Intensification of Canagliflozin Dose from 100 mg to 300 mg Daily in Patients with Type 2 Diabetes in Real Life: The INTENSIFY Study
2023 · Juan J. Gorgojo-Martinez, Pablo José Ferreira-Ocampo, et al. · Journal of Clinical Medicine · 9
PDF
Clinical Practice Guideline for detection and management of diabetic kidney disease: A consensus report by the Spanish Society of Nephrology
2025 · Nuria Montero, Laia Oliveras, et al. · Nefrología (English Edition) · 8
Delphi-based recommendations for the management of cardiovascular comorbidities in patients with psoriatic arthritis and moderate-to-severe psoriasis
2020 · Pedro Zarco Montejo, Raquel Almodóvar González, et al. · Rheumatology International · 8
Real-World Use of Insulin Glargine U100 and U300 in Insulin-Naïve Patients with Type 2 Diabetes Mellitus: DosInGlar Study
2021 · Natalia Duque, Esther Artime, et al. · Advances in Therapy · 6
Oral Semaglutide and Change in Cardiovascular Risk Factors in High-Risk Type 2 Diabetes
2026 · Sharon L. Mulvagh, Silvio E. Inzucchi, et al. · JAMA Cardiology · 5
Guía de práctica clínica sobre detección y manejo de la enfermedad renal diabética: documento de consenso de la Sociedad Española de Nefrología
2024 · Nuria Montero, Laia Oliveras, et al. · Nefrología · 5
Works count: 61
Citation count: 1,025
H-index: 14
I10-index: 20
Year
Topic
Type